SCHEMBL4525490

SCHEMBL4525490

CN(C)C(=O)c1ccc(CC2CCN(C3CCCCC3)C2=O)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.63
CCR5 P51681 1/20 0.45
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
KMT2A Q03164 1/20 0.40
KDM2B Q8NHM5 2/20 0.40
POLB P06746 1/20 0.39
DAGLA Q9Y4D2 1/20 0.39
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38
PSENEN Q9NZ42 1/20 0.38
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HRH3 Q9Y5N1 1/20 0.37
CES2 O00748 1/20 0.37
OPRM1 P35372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4506395 0.86 HSD11B1 (0.67) HSD11B1CCR5KMT2AALDH1A1
SCHEMBL4517638 0.85 HSD11B1 (0.73) HSD11B1CCR5KMT2AALDH1A1HRH3
SCHEMBL4518867 0.83 HSD11B1 (0.63) HSD11B1CCR5LMNAKMT2AALDH1A1
SCHEMBL4518607 0.83 HSD11B1 (0.63) HSD11B1LMNAKMT2AALDH1A1
SCHEMBL208998 0.82 HSD11B1 (0.45) HSD11B1CCR5LMNATP53KDM2B
SCHEMBL3548392 0.82 HSD11B1 (0.76) HSD11B1TP53KMT2AALDH1A1CES2
SCHEMBL4514748 0.78 HSD11B1 (0.74) HSD11B1LMNAKMT2APOLBALDH1A1
SCHEMBL3548948 0.78 HSD11B1 (0.74) HSD11B1LMNATP53
SCHEMBL14365000 0.78 HSD11B1 (0.74) HSD11B1TP53KMT2AALDH1A1CES2
SCHEMBL2986964 0.78 HSD11B1 (1.00) HSD11B1LMNATP53KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885CCR5 2582/4885LMNA 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.